vs
GLOBUS MEDICAL INC（GMED）与罗致恒富（RHI）财务数据对比。点击上方公司名可切换其他公司
罗致恒富的季度营收约是GLOBUS MEDICAL INC的1.6倍（$1.3B vs $826.4M），GLOBUS MEDICAL INC同比增速更快（25.7% vs -5.8%），GLOBUS MEDICAL INC自由现金流更多（$202.4M vs $170.8M），过去两年GLOBUS MEDICAL INC的营收复合增速更高（16.7% vs -6.1%）
Globus Medical是总部位于美国宾夕法尼亚州奥杜邦的上市骨科医疗器械企业，专注于相关产品的设计、研发与商业化，助力外科医生为肌肉骨骼系统疾病患者提供治疗方案，促进患者康复。
罗致恒富是1948年成立的国际人力资源咨询机构，总部位于加利福尼亚州门洛帕克和圣拉蒙，是全球规模领先的会计与金融领域人才派遣服务商之一，在全球范围内设有超过345个办公点。
GMED vs RHI — 直观对比
营收规模更大
RHI
是对方的1.6倍
$826.4M
营收增速更快
GMED
高出31.5%
-5.8%
自由现金流更多
GMED
多$31.6M
$170.8M
两年增速更快
GMED
近两年复合增速
-6.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $826.4M | $1.3B |
| 净利润 | $140.6M | — |
| 毛利率 | 68.4% | 37.6% |
| 营业利润率 | 20.5% | 1.7% |
| 净利率 | 17.0% | — |
| 营收同比 | 25.7% | -5.8% |
| 净利润同比 | 430.4% | — |
| 每股收益（稀释后） | $1.01 | $0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GMEDRHI
| Q4 25 | $826.4M | $1.3B | ||
| Q3 25 | $769.0M | $1.4B | ||
| Q2 25 | $745.3M | $1.4B | ||
| Q1 25 | $598.1M | $1.4B | ||
| Q4 24 | $657.3M | $1.4B | ||
| Q3 24 | $625.7M | $1.5B | ||
| Q2 24 | $629.7M | $1.5B | ||
| Q1 24 | $606.7M | $1.5B |
净利润GMEDRHI
| Q4 25 | $140.6M | — | ||
| Q3 25 | $119.0M | $42.9M | ||
| Q2 25 | $202.8M | $41.0M | ||
| Q1 25 | $75.5M | $17.4M | ||
| Q4 24 | $26.5M | — | ||
| Q3 24 | $51.8M | $65.5M | ||
| Q2 24 | $31.8M | $68.2M | ||
| Q1 24 | $-7.1M | $63.7M |
毛利率GMEDRHI
| Q4 25 | 68.4% | 37.6% | ||
| Q3 25 | 67.2% | 37.2% | ||
| Q2 25 | 66.6% | 37.2% | ||
| Q1 25 | 67.3% | 36.9% | ||
| Q4 24 | 59.9% | 38.8% | ||
| Q3 24 | 56.8% | 39.0% | ||
| Q2 24 | 58.7% | 39.2% | ||
| Q1 24 | 60.2% | 38.1% |
营业利润率GMEDRHI
| Q4 25 | 20.5% | 1.7% | ||
| Q3 25 | 17.9% | 1.0% | ||
| Q2 25 | 10.2% | 0.1% | ||
| Q1 25 | 16.2% | 2.9% | ||
| Q4 24 | 9.2% | 4.7% | ||
| Q3 24 | 7.7% | 4.1% | ||
| Q2 24 | 7.9% | 5.1% | ||
| Q1 24 | 1.3% | 2.8% |
净利率GMEDRHI
| Q4 25 | 17.0% | — | ||
| Q3 25 | 15.5% | 3.2% | ||
| Q2 25 | 27.2% | 3.0% | ||
| Q1 25 | 12.6% | 1.3% | ||
| Q4 24 | 4.0% | — | ||
| Q3 24 | 8.3% | 4.5% | ||
| Q2 24 | 5.0% | 4.6% | ||
| Q1 24 | -1.2% | 4.3% |
每股收益（稀释后）GMEDRHI
| Q4 25 | $1.01 | $0.32 | ||
| Q3 25 | $0.88 | $0.43 | ||
| Q2 25 | $1.49 | $0.41 | ||
| Q1 25 | $0.54 | $0.17 | ||
| Q4 24 | $0.19 | $0.53 | ||
| Q3 24 | $0.38 | $0.64 | ||
| Q2 24 | $0.23 | $0.66 | ||
| Q1 24 | $-0.05 | $0.61 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $557.2M | $464.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $4.6B | $1.3B |
| 总资产 | $5.3B | $2.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资GMEDRHI
| Q4 25 | $557.2M | $464.4M | ||
| Q3 25 | $18.8M | $365.3M | ||
| Q2 25 | — | $380.5M | ||
| Q1 25 | — | $342.5M | ||
| Q4 24 | $890.1M | $537.6M | ||
| Q3 24 | $71.9M | $570.5M | ||
| Q2 24 | $82.5M | $547.4M | ||
| Q1 24 | $80.4M | $540.9M |
股东权益GMEDRHI
| Q4 25 | $4.6B | $1.3B | ||
| Q3 25 | $4.4B | $1.3B | ||
| Q2 25 | $4.3B | $1.3B | ||
| Q1 25 | $4.1B | $1.3B | ||
| Q4 24 | $4.2B | $1.4B | ||
| Q3 24 | $4.1B | $1.5B | ||
| Q2 24 | $4.0B | $1.5B | ||
| Q1 24 | $3.9B | $1.5B |
总资产GMEDRHI
| Q4 25 | $5.3B | $2.9B | ||
| Q3 25 | $5.1B | $2.8B | ||
| Q2 25 | $5.0B | $2.8B | ||
| Q1 25 | $4.7B | $2.7B | ||
| Q4 24 | $5.3B | $2.9B | ||
| Q3 24 | $5.1B | $3.0B | ||
| Q2 24 | $5.0B | $2.9B | ||
| Q1 24 | $4.9B | $2.9B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $248.6M | $182.5M |
| 自由现金流经营现金流 - 资本支出 | $202.4M | $170.8M |
| 自由现金流率自由现金流/营收 | 24.5% | 13.1% |
| 资本支出强度资本支出/营收 | 5.6% | 0.9% |
| 现金转化率经营现金流/净利润 | 1.77× | — |
| 过去12个月自由现金流最近4个季度 | $588.8M | $266.8M |
8季度趋势，按日历期对齐
经营现金流GMEDRHI
| Q4 25 | $248.6M | $182.5M | ||
| Q3 25 | $249.7M | $77.4M | ||
| Q2 25 | $77.9M | $119.4M | ||
| Q1 25 | $177.3M | $-59.3M | ||
| Q4 24 | $210.3M | $154.8M | ||
| Q3 24 | $203.7M | $129.6M | ||
| Q2 24 | $54.3M | $142.0M | ||
| Q1 24 | $52.4M | $-15.9M |
自由现金流GMEDRHI
| Q4 25 | $202.4M | $170.8M | ||
| Q3 25 | $213.9M | $63.6M | ||
| Q2 25 | $31.3M | $104.2M | ||
| Q1 25 | $141.2M | $-71.7M | ||
| Q4 24 | $193.2M | $140.5M | ||
| Q3 24 | $161.7M | $111.8M | ||
| Q2 24 | $26.5M | $129.6M | ||
| Q1 24 | $23.8M | $-27.7M |
自由现金流率GMEDRHI
| Q4 25 | 24.5% | 13.1% | ||
| Q3 25 | 27.8% | 4.7% | ||
| Q2 25 | 4.2% | 7.6% | ||
| Q1 25 | 23.6% | -5.3% | ||
| Q4 24 | 29.4% | 10.2% | ||
| Q3 24 | 25.8% | 7.6% | ||
| Q2 24 | 4.2% | 8.8% | ||
| Q1 24 | 3.9% | -1.9% |
资本支出强度GMEDRHI
| Q4 25 | 5.6% | 0.9% | ||
| Q3 25 | 4.7% | 1.0% | ||
| Q2 25 | 6.2% | 1.1% | ||
| Q1 25 | 6.0% | 0.9% | ||
| Q4 24 | 2.6% | 1.0% | ||
| Q3 24 | 6.7% | 1.2% | ||
| Q2 24 | 4.4% | 0.8% | ||
| Q1 24 | 4.7% | 0.8% |
现金转化率GMEDRHI
| Q4 25 | 1.77× | — | ||
| Q3 25 | 2.10× | 1.80× | ||
| Q2 25 | 0.38× | 2.91× | ||
| Q1 25 | 2.35× | -3.42× | ||
| Q4 24 | 7.94× | — | ||
| Q3 24 | 3.93× | 1.98× | ||
| Q2 24 | 1.71× | 2.08× | ||
| Q1 24 | — | -0.25× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GMED
| Other | $391.8M | 47% |
| Nevro Merger Agreement | $293.6M | 36% |
| Enabling Technologies | $141.0M | 17% |
RHI
| Finance And Accounting | $535.2M | 41% |
| Protiviti | $479.0M | 37% |
| Technology | $156.4M | 12% |
| Permanent Placement Talent Solutions | $102.6M | 8% |
| Other | $29.2M | 2% |
